Dr. Jean-Pierre Latere is the founder and CEO of Esobiotec, a pioneering biotech company specializing in in vivo cell therapy, particularly CAR-T immunotherapy (Chimeric Antigen Receptor), based in Mont-Saint-Guibert, Belgium. Dr. Latere embodies the new African elite with a global execution mindset, combining African intellectual genius, Silicon Valley innovation, and Wall Street financial rigor. Like Pierre and Marie Curie, who pushed the boundaries of science, Dr. Latere opens new frontiers in biotech through an unprecedented formula, while remaining a strategic and visionary entrepreneur.

Starting from an idea inspired by a close relative with cancer, Dr. Latere developed a radical, breakthrough technology capable of reprogramming cells directly in the body (in vivo), bypassing the logistical burdens of traditional CAR-T therapies. His innovative ENaBL platform (Esobiotec Engineered NanoBody Lentiviral), which enables the immune system to attack cancers and provides access to transformative cell therapy treatments in just minutes, exemplifies his pioneering scientific and industrial role, with a strong focus on intellectual property, patent strategy, and deeptech innovation. Dr. Latere translated a complex scientific breakthrough into a clear strategic vision while generating exceptional financial valuation, secured by a robust intellectual property portfolio.